Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis

Cardiac amyloidosis is a restrictive cardiomyopathy that results from the deposition of misfolded light chain or transthyretin proteins, most commonly, in cardiac tissue. Traditionally, treatment options for light chain (AL) and transthyretin (ATTR) amyloidosis have been limited. However, there are...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Kathleen W., Stockerl-Goldstein, Keith E., Lenihan, Daniel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
STATE-OF-THE-ART REVIEW
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609907/
https://www.ncbi.nlm.nih.gov/pubmed/31312767
http://dx.doi.org/10.1016/j.jacbts.2019.02.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609907/
https://www.ncbi.nlm.nih.gov/pubmed/31312767
http://dx.doi.org/10.1016/j.jacbts.2019.02.002

Ejemplares similares